Drug intelligence / Profile preview

STRx Theranostic

Development stage: Preclinical
Lead developer: Starget Pharma
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

STRx Theranostic is a radiopharmaceutical theranostic agent being developed by Starget Pharma. It targets the Cholecystokinin 2 Receptor (CCK2R), which is overexpressed in several solid tumors, including colorectal cancer (CRC) and brain cancer. As a theranostic platform, it is designed to integrate diagnostic imaging and targeted radionuclide therapy, allowing for the identification of patients with high target expression and the subsequent delivery of therapeutic radiation directly to the tumor site. The program is currently in the IND-enabling phase for both CRC and brain cancer indications.

Other names: STRx Theranostic

Targets

CCK2R (Cholecystokinin 2 Receptor)

Beyond the preview

Go deeper on STRx Theranostic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STRx Theranostic.

Explore the full profile